Evelo Biosciences has just forged closer ties with a heavyweight academic partner for its monoclonal microbials R&D, which envisages using bacteria to…

Bay Area drug discovery company Verge Genomics has formed industry and academic alliances in neuro disorders.

The expansion of the deal gives the Roche subsidiary the chance to use Arvinas’ protein degradation technology against additional disease targets.

Loxo predicts the deal for its tropomyosin receptor kinase inhibitor franchise will generate $1 billion over the next few years.

The pact tasks CureVac with developing Cas9 mRNA constructs for use in three in vivo gene-editing liver disease programs.

Aquila BioMedical signed an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs.

The pact sees Boehringer commit to up to €307 million to work with MiNA on up to three targets relevant to NASH and other fibrotic liver diseases.

We kick off a new long form series assessing the life science industry from its leaders with ex-Teva chief Jeremy Levin.

The goal is to use Dicerna’s GalXC technology to silence previously inaccessible drug targets, thereby restoring liver function.